Vanguard Group Inc. raised its holdings in shares of Entellus Medical, Inc. (NASDAQ:ENTL) by 77.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 424,823 shares of the medical technology company’s stock after acquiring an additional 185,833 shares during the quarter. Vanguard Group Inc. owned approximately 2.04% of Entellus Medical worth $5,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Parametric Portfolio Associates LLC boosted its stake in shares of Entellus Medical by 5.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after acquiring an additional 573 shares during the last quarter. Swiss National Bank boosted its stake in shares of Entellus Medical by 98.9% during the 1st quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after acquiring an additional 8,800 shares during the last quarter. TD Asset Management Inc. purchased a new position in shares of Entellus Medical during the 1st quarter worth $279,000. Keybank National Association OH boosted its stake in shares of Entellus Medical by 19.2% during the 1st quarter. Keybank National Association OH now owns 29,359 shares of the medical technology company’s stock worth $405,000 after acquiring an additional 4,721 shares during the last quarter. Finally, Blair William & Co. IL purchased a new position in shares of Entellus Medical during the 1st quarter worth $1,229,000. Institutional investors and hedge funds own 70.41% of the company’s stock.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/08/vanguard-group-inc-has-5-86-million-stake-in-entellus-medical-inc-entl.html.

ENTL has been the topic of several analyst reports. BidaskClub cut shares of Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Canaccord Genuity set a $18.00 target price on shares of Entellus Medical and gave the company a “hold” rating in a research note on Monday, May 22nd. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, ValuEngine upgraded shares of Entellus Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $21.71.

Entellus Medical, Inc. (NASDAQ:ENTL) traded down 0.63% on Friday, hitting $17.49. 38,508 shares of the company were exchanged. Entellus Medical, Inc. has a 52 week low of $11.47 and a 52 week high of $22.63. The company’s market capitalization is $443.74 million. The firm’s 50 day moving average is $17.33 and its 200 day moving average is $15.00.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. During the same period last year, the company posted ($0.27) earnings per share. The business’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) earnings per share for the current fiscal year.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.